Uilyam A. Haseltine - William A. Haseltine - Wikipedia

Ushbu maqola amerikalik olim va tadbirkor haqida. Avstraliya va Buyuk Britaniya rasmiylari uchun qarang Uilyam Heseltin. Avstraliyalik velosipedchi uchun qarang Bill Heseltine. Amerikalik tarixchi uchun qarang Uilyam B. Gesseltin.
Uilyam Alan Haseltine
Uilyam A. Haseltine.jpg
Tug'ilgan1944 yil 17 oktyabr
Sent-Luis, Missuri
FuqarolikQo'shma Shtatlar
Olma materKaliforniya universiteti Berkli,
Garvard universiteti,
Massachusets texnologiya instituti
Tashqi audio
audio belgisi "Pandemiya istiqbollari: Uilyam Xaseltin bilan intervyu", Fan tarixi instituti, 2020 yil 28-may.

Uilyam A. Haseltine (1944 yil 17-oktyabrda tug'ilgan) - bu Amerika olim, ishbilarmon, muallif va xayriyachi. U o'zining poydevorsozlik ishlari bilan tanilgan OIV / OITS va inson genomi. Haseltine professor bo'lgan Garvard tibbiyot maktabi u erda saraton va OIV / OITS bo'yicha ikkita tadqiqot bo'limiga asos solgan. Haseltine bir necha biotexnologiya kompaniyalarining asoschisi, shu jumladan Cambridge Bioscience, Virus tadqiqot instituti, ProScript, LeukoSite, Dendreon, Diversa, X-VAX va Demetrix. U asoschisi raisi va bosh direktori bo'lgan Inson genomi fanlari, genomikani giyohvand moddalarni topishda kashshof bo'lgan kompaniya. U Haseltine Fan va San'at Jamg'armasi prezidenti va butun dunyo bo'ylab yuqori sifatli sog'liqqa kirishni yaxshilashga bag'ishlangan "ACCESS Health International" notijorat tashkiloti asoschisi, raisi va prezidenti. U tomonidan ro'yxatga olingan Time jurnali 2001 yilda dunyodagi eng nufuzli 25 ishbilarmon kishilardan biri va biotexnologiyaning 100 ta eng nufuzli rahbarlaridan biri sifatida[1] tomonidan Ilmiy Amerika 2015 yilda.

Dastlabki hayot va ta'lim

Haseltine o'z faoliyatini inson salomatligini yaxshilashga bag'ishlagan. U ilmiy oilada tug'ilgan. Uning bobosi an muhandis, uning otasi a Ph.D. fizik. U katta bo'lgan Dengiz Ornance sinov stantsiyasi Xitoy ko'lida Mojave sahrosi ning Kaliforniya, qurol olimlari va muhandislari bilan o'ralgan. Uning katta singlisi Florensiya ikkalasi ham doktorlik dissertatsiyasini olgan. yilda biofizika va an M.D. va uning ukasi Erik fan nomzodi yilda neyrobiologiya. Uning singlisi Syuzan kompyuter tizimlari bo'yicha mutaxassisga aylandi. Uning dastlabki hayoti kitobda tasvirlangan Rapture Brayan Aleksandr (1d) va Gen ustalari Ingrid Vinkelgren (3d) tomonidan.

Haseltine bitirgan Sherman E. Burrouz o'rta maktabi 1962 yilda u oldi B.A. yilda kimyo dan Berkli Kaliforniya universiteti 1966 yilda va fan nomzodi. biofizikada Garvard universiteti 1973 yilda.

Biotibbiy tadqiqotlar bo'yicha mashg'ulotlar

Tibbiyotgacha bo'lgan kimyo ixtisosligi bo'yicha bakalavriat talabasi sifatida u ikkita ilmiy ishini nashr etdi, bittasida Mars atmosferasi tarkibi to'g'risida Ilm-fan[2] izotoplardan lazer yordamida kosmosga chiqish uchun bir soniya, amaliy fizika xatlarida.[3] U saylangan Phi Beta Kappa uning kichik yili va sinfining yuqori qismida bitirgan. Bitirgandan so'ng u kasallikni davolash va davolashning yangi usullarini yaratish yo'lida ilm haqida iloji boricha ko'proq ma'lumot olishga qaror qildi.

Garvard universitetida u DNK tuzilishini birgalikda kashf etgan Jeyms D. Uotson va keyinchalik DNK ketma-ketligini aniqlash usulini ishlab chiqqanligi uchun Nobel mukofotiga sazovor bo'lgan Valter Gilbert rahbarligida ishlagan. Ushbu laboratoriyada ishlash unga o'sha paytdagi yangi molekulyar biologiya sohasi vositalarida mukammal asos yaratdi. Aspirant sifatida u genlarning ekspressionatsiyasini tartibga solishning asosiy jihatlari ustida ishlagan. U bakteriyalar oziq-ovqat ko'p bo'lganda o'sishdan parhez kam bo'lganda parvarishlashga o'tishini bildiruvchi vositalarni yoritib berdi, nomzodlik dissertatsiyasi mavzusi Sehrli nuqta va qattiq javob.[4][5][6][7][8]

Magistratura bosqichida Haseltine Vetnamdagi urushga qarshi chiqishida ham faol bo'lgan. U Vetnam urushida texnologiyalardan foydalanish bo'yicha bir nechta maqolalar yozgan va "Agent Orange Defoliation" hikoyasini buzgan. Yangi respublika.[9] U bilan ishlagan Amerika do'stlariga xizmat ko'rsatish qo'mitasi o'z jamoalarining urushda ishtirok etishini tushunishni istaganlar va butun mamlakat bo'ylab bir necha yil davomida urushga qarshi ma'ruzalar qilganlar uchun resurs markazini yaratish. U asoschisi edi "Xalq uchun fan ".

1973 yilda Haseltine laboratoriyasiga qo'shildi Devid Baltimor da Massachusets texnologiya instituti post-doktorant sifatida. U erda u qanday qilib asosiy jihatlar ustida ishlay boshladi retroviruslar hayvonlarda saraton kasalligini keltirib chiqarishi ma'lum. Uning ishi boshqa bir qancha olimlar bilan hamkorlikda retrovirus replikatsiyasi jarayoni to'g'risida kutilmagan tushunchalar berdi va etakchi ilmiy jurnallarda nashr etishda innovatsion deb topildi.[10][11][12][13][14] Ushbu ish uni inson kasalliklari va retroviruslari bo'yicha tadqiqotlarga tayyorladi, bu ularning keyingi faoliyatida muhim edi.

U 1973 yil yozida MITda doktorlikdan keyingi o'qishini to'xtatib, tashrif buyurgan professor bo'lib xizmat qildi Kopengagen universiteti sog'liqni saqlash va tibbiyot fanlari fakulteti, u erda bakteriyalarda gen ekspressionini tartibga solish bo'yicha ishini davom ettirdi.[15]

Saraton kasalligini o'rganish

1976 yilda u yangi kompleks saraton markazi fakultetiga qo'shildi Dana Farber saraton instituti bilan bog'liq Garvard tibbiyot maktabi. U Garvard tibbiyot fakulteti patologiya kafedrasi professori va ko'p o'tmay saraton biologiyasi kafedrasi professori bo'ldi. Garvard sog'liqni saqlash maktabi. U ikkita akademik kafedraning baravariga asos solgan: saraton kasalligini davolash va davolash bo'yicha biokimyoviy farmakologiya laboratoriyasi va OITS / OITSni davolashga bag'ishlangan, tushunadigan va topadigan odam retrovirologiyasi bo'limi. Professor sifatida u etakchi ilmiy jurnallarda ikki yuzdan ortiq ilmiy maqolalarini nashr etdi va bir nechta kitoblarni tahrir qildi. U o'nlab aspirantlar va aspirantlarga ustozlik qildi, ularning aksariyati Garvardda va boshqa joylarda o'zlarining muvaffaqiyatli martabalarini boshladilar. U aspirant va tibbiyot talabalariga saraton biologiyasi va OIV / OITS bo'yicha yuqori darajadagi kurslarni o'rgatdi. U ko'p yillar davomida Garvardning ilmiy bo'lmagan magistrantlari uchun "Biologiya va ijtimoiy muammolar" kursini o'qitgan va Garvard talabalari biokimyosi talabalarining bir necha avlodlari uchun o'qituvchi va tezis bo'yicha maslahatchi bo'lgan.

Retrovirusni ko'paytirish Garvard professori sifatida o'zining dastlabki tadqiqotlari markazida bo'lib qoldi. Ushbu tadqiqot genomning dastlabki nusxasini "oxirigacha sakrash" ni o'z ichiga olgan fundamental tushunchalarga olib keldi.[16][17][18][19][20][21] Keyin u ikkita bog'liq masalaga e'tibor qaratishni boshladi: retroviruslar hayvonlarda saraton kasalligini qanday keltirib chiqaradi va retroviruslar odamlarda saraton va boshqa kasalliklarni keltirib chiqaradimi yoki yo'qmi.[22][23][24][25][26][27][28] Uning laboratoriyasi retroviruslarning, onkogenlarni tashimaydigan, saraton kasalligini keltirib chiqaradigan asosiy omil ularning tez o'sadigan hujayralarda tez ko'payish qobiliyatidir.[29][30][31] Bu retrovirusga uyali onkogenni joylashtirishi mumkin. Ushbu ishning ilm-fan uchun yana bir ta'siri, transkripsiyani boshlash joyining yuqorisida kichik genetik elementlar, hozirda kuchaytiruvchi deb nomlangan, genlarning RNKga ko'chirilish tezligini aniqlaganligi edi. Ushbu kashfiyot bir hujayra turini boshqasidan ajratib turadigan omillar to'g'risida asosiy tushuncha berdi.[32]

1978 yilda saraton kasalligini davolash bilan shug'ullanadigan shifokorlarning ehtiyojlariga javoban Haseltine saraton kasalligini davolash uchun ishlatiladigan dorilar va nurlanish qanday ishlashini chuqur anglab, kimyoviy terapiyani yaxshilashga e'tibor qaratishni boshladi. Saratonga qarshi ko'plab davolanishlar DNKga zarar etkazish orqali tez o'sayotgan saraton hujayralarini o'ldirdi. Haseltine laboratoriyasi DNKning zararlanishini va uning tiklanishini tushunishda DNKni sekvensiyalashning yangi usullarini birinchilardan bo'lib qo'llagan.[33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] Ushbu tadqiqotlar ko'plab saraton kasalligini davolash usullari to'g'risida chuqurroq ma'lumot olishga olib keldi va Biokimyoviy farmakologiya bo'limini yaratishga asos bo'ldi. Kashfiyotlar Dana Farber saraton kasalligi instituti prezidenti Emil Frei tomonidan bosh va bo'yin saratonini davolash bo'yicha yangi yondashuvlarning dizayni haqida ma'lumot berdi. Oxir oqibat doktor Frei boshchiligidagi guruh bosh va bo'yin saratoniga chalingan bemorlarning 5 yillik hayotini 20% dan 80% gacha oshirishda muvaffaqiyatli bo'ldi. Bo'lim saraton farmakologiyasiga ixtisoslashgan yangi avlod shifokorlari / olimlarini tayyorlash vazifasini ham o'z zimmasiga oldi.

Laboratoriya bu ishni saratonga olib keladigan kimyoviy moddalar va radiatsiya DNKning o'zgarishiga olib keladigan saraton jarayonini o'rganish uchun kengaytirdi.[49][50][51][52][53][54][55][56][57][58] Ushbu ishda quyosh ta'sirida DNKning zararlanishining yangi va kutilmagan shakli aniqlanib, 6-4 lezyon deb nomlangan bo'lib, melanomani, shu jumladan saraton kasalligini keltirib chiqaradigan quyosh nurlari ta'sirida terining aksariyat mutatsiyalari uchun javobgardir.[59][60][61][62][63][64][65]

Inson T hujayralari leykemiya virusi

Haseltine retroviruslar inson kasalliklarida muhim rol o'ynagan degan tushuncha ustida ishlashni davom ettirgan 1970-yillarning oxirlarida juda kam bo'lgan olimlardan biri edi. Bir paytlar 1960-yillarning oxiri va 70-yillarning boshlarida ommalashgan ushbu g'oya butun dunyo bo'ylab laboratoriyalar tomonidan o'n yil yoki undan ko'proq vaqt davomida odamning retroviruslarini behuda izlashdan keyin tark etildi. Haseltine, boshqa bir qancha olimlar bilan ishlashda, odamning retroviruslari sichqonlar kabi laboratoriya hayvonlariga ta'sir qiladigan narsalardan boshqacha yo'l tutadi va o'zlarini laboratoriya bo'lmagan hayvonlarda saraton kasalligi va immunologik nuqsonlarni keltirib chiqaradigan kabi tutadi deb o'ylardi.[66][67][68][69][70][71][72][73][74][75][76] Ushbu viruslar erta yuqtirilgandan so'ng yo'q bo'lib ketadigandek tuyuladi, kasallik faqat bir necha yildan so'ng paydo bo'ladi. Haseltine o'z laboratoriyasining bir qismini ushbu hayvonlarning retroviruslarini o'rganishga bag'ishladi, chunki ular inson kasalligi to'g'risida tushuncha beradi. 1978 yilda u Dana Farber saraton institutida ushbu viruslar aniqlanganda ular ustida ishlash uchun maxsus saqlash laboratoriyasini loyihalashtirishga yordam berdi, bu uning OIV / OITSga qarshi ishi uchun juda zarur edi.

1979 yilda inson kasalligini keltirib chiqargan birinchi odam retrovirusi - inson T hujayrasi leykemiya virusi (HTLV). HTLV jinsiy yo'l bilan erkaklardan ayollarga, ayollar o'z farzandlariga va qon quyish orqali yuqadi. Kasallik, T-hujayrali leykemiya, infektsiyadan o'nlab yillar o'tgach paydo bo'ladi. Haseltine va uning laboratoriyasi HTLV transaktivator X (hozirda shunday nomlangan) deb nomlangan yangi genni olib borishini aniqladi soliq).[77][78][79][80][81] Keyingi bir necha yil ichida Haseltine va uning hamkasblari buni ko'rsatdilar soliq saraton kasalligi uchun javobgar bo'lgan gen.[82][83][84][85][86][87] Xaseltin 1983 yil yozida Kioto Universitetida mehmon professor sifatida bo'lib Yaponiyada tarqalgan virus bo'lgan Human T hujayra Leykemiya virusini o'rganayotgandi.[88]

OIV / OITS tadqiqotlari va davlat siyosati

HTLV ishi Haseltineni OITS bilan ishlashga tayyorladi. OITS epidemiyasi aniqlanmasdan oldin Haseltinening tajribasi va odamning retroviruslarini o'rganish uchun imkoniyatlari bor edi. U birinchi marta 1981 yil oxirida hamkasblaridan yangi kasallik haqida bilib oldi. 1982 yil boshida u va HTLV ustida ish olib borgan bir qancha olimlar yangi kasallikning sabablarini aniqlash uchun kichik ishchi guruh tuzdilar. Ular 1982 yil boshidan 1985 yilgacha har 4-6 xaftada muntazam uchrashib turdilar. Kasalliklarni nazorat qilish markazlarining yordami bilan ushbu guruh OITSga odamning HTLVga o'xshash retrovirusi sabab bo'lgan degan gipotezani shakllantirishdi. Ular ushbu yangi virusni topish uchun HTLV virusini ajratishda ishlatiladigan usullarga o'xshash usullardan foydalanishni taklif qilishdi. Ushbu usullar hozirgi kunda inson immunitet tanqisligi virusi (OIV) deb nomlangan virusni ajratish va uning OITS sababi ekanligini isbotlash uchun muvaffaqiyatli ishlatildi.

Keyingi o'n yil davomida Haseltine o'z kuchini OIV / OITSni aniqlash, davolash va oldini olish yo'llarini izlashga bag'ishladi. U kasallikning xavfliligini birinchilardan bo'lib tan oldi va epidemiyaning kattaligini aniq bashorat qildi. Uning fikrlari kitobda qisqacha bayon qilinganidek, juda ziddiyatli hisoblanadi Geteroseksual yordam haqidagi afsona: Ommaviy axborot vositalari va partizan siyosat tomonidan fojia qanday buzilgan? Maykl Fumento tomonidan.[89] "20 yil oldin" Discover: Noto'g'ri tushunish OITS "deb nomlangan retrospektiv maqolada, Jurnalni kashf eting 1980-yillarning o'rtalarida intervyu bergan 20 nafar olimlardan biri sifatida Haseltine-ni OITS / OITS yuqtirishni anal jinsiy aloqa va umumiy ignadan foydalanish bilan cheklash mumkin emasligini, ammo heteroseksual hamjamiyatda tarqalishi va bo'lish qobiliyatiga ega ekanligini to'g'ri tushungan. global pandemiya.[90]

Xaseltinning epidemiyaga munosabati uch xil edi:

  1. Farmatsevtika va biotexnika kompaniyalariga epidemiyaga qarshi kurashish uchun yangi bilimlar zarurligini anglab, kasallikni aniqlash, davolash, davolash va oldini olish vositalarini kashf etishlari uchun virusni etarlicha chuqur o'rganish uchun laboratoriya tadqiqotlarini o'tkazish.
  2. Epidemiya sezilarli darajada o'sib borishi va o'nlab yillar davomida olib boriladigan izlanishlar talab qilinishini anglab, saraton kasalligini tadqiq qilishga bag'ishlanganlar singari epidemiya bo'yicha tadqiqotlar olib boradigan yangi muassasalar yaratilishini rag'batlantirish.
  3. Tadqiqotni qo'llab-quvvatlash va o'n millionlab odamlar kasallikka chalinganligini anglab, yuqtirganlarni insoniy va sezgir qo'llab-quvvatlash uchun ushbu kasallik to'g'risida jamoatchilik xabardorligini oshirish.

Birinchi maqsadga virusning tuzilishi va funktsiyasini tushunish orqali erishildi. Haseltine laboratoriyasi boshqa ikkita guruh bilan hamkorlikda virus genomining to'liq ketma-ketligini aniqladi va virus kapsidi, polimeraza, proteaz, ribonukleaz H, integral va genlarni o'rab turgan genlarni aniqladi.[91] Ushbu bilimlarning birinchi qo'llanilishi aniq tashxisiy testning asosini tashkil etgan holda, virusni yuqtirganlarda OIVga qarshi antikorlarni aniq aniqlash uchun ishlatilishi mumkin bo'lgan virus konvertlari oqsilining bir qismini loyihalashtirish edi. Ushbu protein parchasi Cambridge BioScience (keyinchalik Cambridge BioTech deb nomlangan) tomonidan uyda ishlatilishi mumkin bo'lgan OIV infektsiyasiga tezkor test ishlab chiqish uchun ishlatilgan. Faqat 2012 yilda AQSh FDA shu kabi uy sharoitida OIVga qarshi test vositasini tasdiqladi.Haseltin va uning laboratoriyasi tezda virus kapsidi, polimeraza, proteaz, ribonukleaza, integrala va konvert genlarini ko'rsatadigan virus genlarining zararlanishi virusni o'ldirganligini ko'rsatdi. va shuning uchun har bir gen tomonidan ko'rsatilgan oqsillar virusga qarshi dorilar uchun yaxshi maqsad bo'lgan. Keyingi bir necha yil ichida uning laboratoriyasi genlarning har birini va ularning oqsillarini sof holda ajratib oldi va farmatsevtika kompaniyalari tomonidan virusga qarshi yangi dorilarni topish uchun ishlatilgan usullarni ishlab chiqdi. Birinchi OIVga qarshi proteaz inhibitori Nelfinavir Haseltine laboratoriyasi, Camelt BioScience, Haseltine kompaniyasi va uning hamkasblari tomonidan yaratilgan Agouron Pharmaceuticals kompaniyasi bilan uch tomonlama hamkorlikning bir qismi sifatida ishlab chiqilgan. AZT va anti-proteaz preparati kabi OIV polimeraza inhibitori kombinatsiyasi OIV bilan kasallanganlarning birinchi uzoq muddatli omon qolishiga olib keladi. Haseltine turli xil virusli oqsillarga qarshi bir nechta dori-darmonlarni samarali terapiya uchun asos qilib olgan holda kombinatsiyalangan kimyoviy terapiyani qo'llashni taklif qildi.[92][93][94][95][96][97][98][99] Bugun bu g'oyalar isbotlandi; farmatsevtika sanoati OIV polimeraza, proteaza, integralaza va konvert oqsillarini inhibe qiladigan qirqdan ortiq dori vositalarini ishlab chiqdi. Ushbu dorilarning kombinatsiyasi OIV infektsiyasini umumiy o'limga olib keladigan kasallikdan, to'g'ri davolash bilan odatda o'nlab yillar davomida muvaffaqiyatli davolanadigan kasallikka aylantirdi.

OIV genomi bir nechta qo'shimcha sirlarni taqdim etdi. Virus genomida hali noma'lum oqsillarni ko'rsatishi mumkin bo'lgan hududlar mavjud edi. Haseltine laboratoriyasi virusni ko'paytirish uchun zarur bo'lgan yangi transaktiv oqsil va ikkinchi oqsilni kashf etdi. Ular transaktivatorga tat deb nom berishdi [84][100][101][102][103][104] va ikkinchi oqsil san'ati; ikkinchisi rev deb o'zgartirildi.[105][106][107][108][109][110][111][112] Uning ta'kidlashicha, ushbu oqsillarga mo'ljallangan dorilar ham infektsiyani davolashda samarali bo'ladi. Inhibe qiluvchi dori rev protein OIV infektsiyasini davolash uchun AQSh oziq-ovqat va dori-darmonlarni boshqarish tomonidan tasdiqlangan. Uning laboratoriyasi qo'shimcha virusli genlar va oqsillarni topishga kirishdi - vpr,[113][114][115][116] vpu,[117][118][119][120] vif,[121] va nef[122][123][124][125][126] - ba'zi sharoitlarda, ammo barcha sharoitlarda virusning samarali o'sishi uchun zarur. Kashfiyotlar 1988 yilda chop etilgan maqolada qisqacha bayon qilingan Ilmiy Amerika.[127]

Ushbu davrda uning laboratoriyasi epidemiyani tushunish va boshqarishda yordam beradigan boshqa ilmiy kuzatuvlarni olib bordi. Uning laboratoriyasi shuni ko'rsatdiki, reproduktiv traktning shilliq pardalari orqali oldinga va orqaga o'tadigan dendritik hujayralar infektsiyani boshlash uchun OIVni tanaga tashiydi.[88][128][129] U kasallikning maymun modellarini o'rganish uchun yollagan hamkasbi bilan ish olib borganida, u onadan bolaga yuqish holatini kamaytirish mumkinligini ko'rsatdi, buning iloji borligining birinchi isboti.[130]Uning laboratoriyasi birinchi bo'lib hujayralarga begona genlarni kiritish uchun OIVning zaiflashgan shaklidan foydalangan va hozirgi kunda "gen terapiyasi uchun lentivirus vektorlari" deb nomlangan.[131] Laboratoriya shuningdek, yangi maymun va vaksinalarni primat modellari yordamida yaratish uchun maymun va ba'zi OIV genlarini - SHIV viruslarini olib yuradigan gibrid viruslarni yaratdi.

Haseltine birinchilardan bo'lib OIVga qarshi vaktsina ishlab chiqilishiga shubha bilan qaraladi. 1986 yilda Parijda bo'lib o'tgan OIV / OITS bo'yicha ikkinchi xalqaro yig'ilishda u infektsiya paytida odamning immunitet reaktsiyasi to'liq faollashishini, antiviral antitellar darajasi yuqori ekanligini va hujayra vositachiligida immunitet to'liq faolligini, ammo infektsiya davom etayotganini ta'kidladi. Shu sababli, biron birini yoki boshqasini yoki ikkalasini qo'zg'atadigan ma'lum bo'lgan emlash texnologiyalari ishlamasligi mumkin edi. O'sha paytda juda mashhur bo'lmagan ushbu g'oya bashoratli edi. Xulosa shuni anglatadiki, kasallikni nazorat qilish bo'yicha harakatlar tashxis qo'yish, davolash va vaksina sifatida ta'limga yaqin orada kelmaydi.

O'n yillik ishdan so'ng birinchi maqsad amalga oshirildi. OIV / OITS diagnostikasi va davolashga ratsional yondashuvning ilmiy asoslari yaratildi, zarur vositalar tayyor edi. Virusga qarshi dori-darmonlarni kombinatsiyalashgan davolashning muvaffaqiyati bugungi kunda ushbu asoslarga asoslanadi.

Ikkinchi maqsad OIV / OITS epidemiyasini nazorat qilish uchun zarur bo'lgan tadqiqotlarni olib borish uchun yangi institutlarni yaratishga yordam berish edi. Epidemiyaning dastlabki yillarida ilmiy jamoalarda bunday ish uchun ozgina pul yoki ishtiyoq bor edi. Epidemiya tahdidi ko'pchilikka ko'rinmas edi, masalan, Sog'liqni saqlash vazirligi va 1986 yilda Kongressga OIV / OITS tadqiqotlari uchun Milliy Sog'liqni Saqlash Institutlariga (NIH) bir million dollar ajratilishi to'g'risidagi tavsiyasida aks etgan. 1986 yil yozining oxirida aktyor Rok Xadson Parijda OITS bilan kasal bo'lib, uni Los-Anjelesga etkazib berishdi. Bu OIV / OITS bo'yicha tadqiqotlarni qo'llab-quvvatlashni boshlash uchun bir lahza bo'lishi mumkinligini tushunib, Haseltine yangi tashkil etilgan Amerika OITSga qarshi tadqiqotlar fondi (AMFAR) va Lasker fondi a'zolari bilan ishlagan Elizabeth Teylordan yordam so'radi. . Olti haftalik davrda ushbu kichik guruh senatorlar Ted Kennedi va Ted Stivensning qo'llab-quvvatlashi bilan Kongressni OIV / OITS tadqiqotlari uchun maxsus NIH byudjetiga qo'shimcha mablag 'sifatida taxminan 320 million dollar qo'shishga ishontirishga muvaffaq bo'lishdi. kitob Rapture[132]). Haseltine ushbu mablag'larning qanday ishlatilishini yo'naltirishga yordam berish uchun Milliy Allergiya va Yuqumli kasalliklar instituti (NIAID) kengashiga tayinlandi. Keyingi bir necha yil ichida OIV / OITS bo'yicha tadqiqotlarni moliyalashtirish yiliga qariyb 2 milliard dollarga o'sdi. Ushbu mablag'lar OIV / OITS epidemiyasini nazorat qilish bo'yicha kuchli ilmiy-tadqiqot institutlarini, minglab olimlar va shifokorlarni tayyorlagan va kasallikni davolash, davolash va oldini olishning eng yaxshi usullarini izlayotgan muassasalarni yaratishda muhim rol o'ynadi. Haseltine Xalqaro OITS tadqiqotlari jamiyatini, hozirda Xalqaro OITS Jamiyatini yaratishda muhim rol o'ynagan va OITS Research and Human Retroviruses ilmiy jurnalining asoschisi muharriri bo'lgan.

Keyinchalik Haseltine yangi viruslarga qarshi dorilarni yaratish uchun akademik laboratoriyalardan farmatsevtika va biotexnologiya kompaniyalariga bilimlarni uzatish dasturlarini ishlab chiqishda yordam berdi. Dastlab farmatsevtika kompaniyalari OIV / OITS bo'yicha yangi tadqiqot dasturlarini boshlashni xohlamadilar. Biotexnologiya kompaniyalari bunday ish uchun zarur mablag 'va tajribaga ega emas edilar. Ushbu muammoni hal qilish uchun Haseltine NIAIDga farmatsevtika va biotexnika kompaniyalarini OIV bilan bog'liq muammolar ustida ishlashni rag'batlantirish uchun maxsus grant dasturini yaratishni taklif qildi. Ushbu dasturga muvofiq akademik olimlarga nisbatan katta miqdordagi mablag 'ajratildi, agar ularning laboratoriyasida bilimlarini yangi dori-darmonlarga tarjima qilishga qodir bo'lgan farmatsevtika yoki biotexnologiya bo'yicha sherik bo'lsa. Ushbu grantlar mablag'larining aksariyati sanoat bo'yicha sherikga yangi dori-darmonlarni tadqiq qilish faoliyatini rivojlantirishni rag'batlantirish uchun sarflandi. Ushbu dori-darmonlarni rivojlantirish bo'yicha to'g'ridan-to'g'ri grantlar to'g'ridan-to'g'ri OIV / OITSni davolash jarayonini o'zgartirgan proteaz inhibitörlerinin kashf qilinishiga olib keldi va keyinchalik integral va zarf oqsillarini samarali yo'naltiradigan dorilar paydo bo'ldi.

1992 yilga kelib, OITS virusi birinchi marta tan olinganidan atigi o'n yil o'tgach, bugungi kunda OIV / OITS tadqiqotlarini olib boradigan muassasalar yaratildi va hanuzgacha faoliyat ko'rsatmoqda.

Epidemiyaning dastlabki kunlarida Haseltine jamoatchilik idrokida ikki martalik muammoni tan oldi. Ilmiy / tibbiyot hamjamiyati ichida ham, tashqarisida ham ko'pchilik epidemiya hech qachon aholi uchun jiddiy xavf tug'dirishiga ishonmagan. Boshqalar OITS bilan kasallanganlar darhol yuqtirish xavfini tug'diradi va ulardan saqlanish kerak, deb hisoblashadi. Ushbu muammoni hal qilish uchun Haseltine turli xil guruhlarni yaratish va ularga rahbarlik qilishga yordam beradi. Ulardan eng muvaffaqiyatli biri Amerika OITSni o'rganish fondi edi. Haseltine AMFAR ilmiy maslahat kengashining birinchi raisi bo'ldi. Missiya ikki xil edi: OIV / OITS bilan ishlashni boshlashni istaganlar uchun grantlar ajratish va OIV / OITSni tahqirlash. OIV / OITSning bugungi ko'plab etakchilari AMFAR tomonidan birinchi yordamni olishdi. Ikkinchi maqsad, epidemiyaning xavfi va kattaligi to'g'risida gapirishga tayyor bo'lgan ilmiy va tibbiy mutaxassislar guruhini ta'minlash va kasallikning yuqumli kasalligidan xavotirda bo'lganlar uchun ishonchli ma'lumotnoma berish edi, boshqacha qilib aytganda malakali mutaxassislar guruhi haqida gapirish kasallikning haqiqiy xavfi va asossiz qo'rquvga qarshi turish. AMFAR bugun ham ushbu rolda davom etmoqda.

Haseltine, shuningdek, xalqaro idrokning ushbu masalalari bo'yicha xalqaro miqyosda ishlagan. U malika Diana bilan yaqindan hamkorlik qilgan Buyuk Britaniyadagi AIDS Crisis Trust konsultanti bo'ldi. Ehtimol, malika Diana har qanday odamdan ko'ra ko'proq kasallikka chalinganlarni kamsitishga va qo'rquvni kamaytirishga, kattalar OITS bilan kasallanganlarni quchoqlashga va OITS bilan kasallangan bolalarni ushlab turishga tayyorligi bilan xizmat qilgan. Haseltine bir muncha vaqt dizayner Valentino tomonidan OIV xurujiga qarshi kurashish uchun tashkil etilgan L.I.F.E. guruhi bilan ham ishlagan. 1986 yildan 1990 yilgacha Haseltine AQShda va undan tashqarida ko'plab radio va televidenie dasturlarida epidemiya xavfidan ogohlantirish va kasallikni qoralash uchun chiqdi.

Biotexnologiya

Uilyam Xaseltin biotexnologiya sohasida ham faol ishlagan. U bir nechta kompaniyalarning asoschisi, venchur kapital guruhlarining maslahatchisi va yirik biotexnologiya kompaniyasi Human Genome Sciences kompaniyasining asoschisi, raisi va bosh direktori bo'lgan. Xaseltinning biotexnologiya va farmatsevtika kompaniyalariga qiziqishi uning yangi bilimlarni kasalliklarni davolash va davolashning yangi usullariga o'tkazish istagidan kelib chiqqan.

1981 yilda u hayvonlarga qarshi yangi avlod vaktsinalarini yaratish uchun Cambridge BioScience-ga asos solgan. Frantsiyaning Virbac kompaniyasi uchun ishlab chiqarilgan birinchi mahsulot uy mushuklarini mushuk leykemiya virusi yuqishidan himoya qilish uchun emlash edi. Kompaniya vaktsinani kuchliroq qilish uchun rekombinant virusli oqsil va yangi qo'shimchani - Stimulondan foydalangan holda samarali emlashni ishlab chiqardi. Bu sutemizuvchilarni retrovirus infektsiyasidan himoya qiluvchi birinchi emlash edi. Kembrij BioScience, shuningdek, birinchi anti-OIV proteazasi Nelfinavirni yaratishda ishtirok etdi.

1987 yilda Haseltine Healthcare Ventures venchur kapital kompaniyasining maslahatchisi bo'ldi. Keyingi bir necha yil ichida ular har biri turli fan va tibbiyot sohasida ishlaydigan bir nechta biotexnologiya kompaniyalariga asos solishdi.

1980-yillarning oxirida Haseltindan Garvardning bir nechta hamkasblari o'z kompaniyalarini yaratishda yordam berishni so'rashdi. ProScript Inc orasida ProScript ko'plab miyeloma va boshqa saraton kasalliklari uchun samarali davolash vositasi bo'lgan oqsil inhibitori bo'lgan Velcade preparatini kashf etdi. Haseltine va hamkasbi, shuningdek, otoimmun kasalliklarni davolash uchun dori ishlab chiqarish uchun LeukoSite Inc. LeukoSite, shuningdek dastlab Healthcare Ventures tomonidan moliyalashtirilib, ProScript-ni sotib oldi, bu esa o'z navbatida Velcade-ni bozorga muvaffaqiyatli olib chiqqan Millenium Pharmaceuticals kompaniyasi tomonidan sotib olindi. Millennium 2008 yilda Takeda farmatsevtika kompaniyasi tomonidan sotib olingan. Bugungi kunda Velcade ko'p miqdordagi miyelomni davolashda muhim dori hisoblanadi.

OIV infektsiyasida dendritik hujayralar ahamiyatini bilish saraton kasalligining immunitet hujayralari terapiyasini yaratgan kompaniyaning shakllanishiga olib kelgan tushuncha berdi. Haseltine Healthcare Ventures bilan birgalikda saraton kasalligini davolash uchun dendritik hujayralardan foydalanish uchun Activated Cell Therapy Inc kompaniyasini tashkil etdi. Oxir-oqibat kompaniya Dendreon Corp deb o'zgartirildi va metastatik prostata saratonini davolash uchun birinchi tasdiqlangan hujayra asosidagi immunologik terapiya Provenge-ni bozorga olib chiqdi. Haseltine, shuningdek, Diversa nomli kompaniyaning asoschisi bo'lgan. Dastlab u "Industrial Genome Sciences Inc" deb nomlangan bo'lib, kompaniya sanoat va tijorat maqsadlarida ishlatiladigan fermentlarni aniqlash uchun genomikadan foydalanadi. Diversa 2007 yilda o'z nomini Verenium korporatsiyasi deb o'zgartirgan va 2013 yil 31 oktyabrda BASF korporatsiyasi tomonidan sotib olingan. Haseltine va uning hamkasblari 2016 yilda ikkita yangi biotexnologiya kompaniyalari - X-VAX va Demetrixga asos solishgan.

Inson genomi fanlari

1992 yil boshida Haseltine "Human Genome Sciences" ga asos solgan. U kompaniyaning dastlabki o'n ikki yilida asoschilar raisi va bosh ijrochi direktori bo'lib ishlagan.

Haseltine OIV genomiga oid bilimlarni tizimli ravishda qo'llashdan to giyohvand moddalarni topishga qadar yangi usullarning fundamental biologik kashfiyot uchun ham, giyohvand moddalar ishlab chiqarish uchun ham qanchalik kuchli ekanligini bilar edi. Aslida OIV genomi bilan ishlash genomni o'rganish natijasida paydo bo'lgan yangi organizm haqida birinchi marta bilim bo'lishi mumkin. OIV / OITSga qarshi giyohvand moddalarni ishlab chiqarish tarixi bunday ma'lumotlarning qanchalik foydali bo'lishi mumkinligini isbotladi. Aslida bu OIVga qarshi samarali dorilarni tez va muvaffaqiyatli ishlab chiqish uchun asos bo'ldi.

Haseltine yangi, yirik farmatsevtika kompaniyasini yaratishni taklif qildi, u nafaqat dori-darmonlarni kashf etish uchun kuchli yangi vositalar to'plamini yaratishga, balki ushbu vositalarni o'z dori-darmonlarini topish, ishlab chiqarish va sotishda ham qo'llanilishi mumkin. Yigirma yil davomida amalga oshirilishini taxmin qilgan ushbu tasavvurni qo'llab-quvvatlash uchun u kompaniyaga genlarni topish vositalariga huquqlarini boshqa farmatsevtika kompaniyalari bilan bo'lishish orqali pul yig'ishni taklif qildi. Ushbu g'oya kompaniyaning asoschisi bo'ldi.[132][133][134][135][136][137][138][139]

1993 yil aprel oyida SmithKline Beecham Genom kashfiyotining yangi vositalariga kirish uchun Human Genome Sciences-ga sarmoya kiritdi. Dastlabki 125 million dollarlik operatsiya o'sha paytda yangi paydo bo'lgan biotexnologiya kompaniyasi tomonidan olingan eng katta mablag 'edi. Bir yildan so'ng Human Genome Sciences va SmithKline Beecham Human Genome Sciences kashfiyot vositalariga kirish huquqini boshqa bir qator farmatsevtika kompaniyalariga, shu jumladan Yaponiyaning Takeda, Germaniyaning Merck, AQShning Schering Plough va Frantsiya kompaniyalariga sotish orqali yana 320 million dollar ajratdilar. Sanofi.

O'sha paytda yangi ajratilgan odamning noma'lum funktsiyali genlari giyohvand moddalarni ishlab chiqarishda foydali bo'lishi mumkin degan fikr keng tanqid qilindi.[133][139] Xaseltinning OIV bilan kasallanish tajribasi unga genom haqida oldindan ma'lumotga ega bo'lmagan bilimlar foydali bo'lganligi va giyohvand moddalarning yangi va foydali maqsadlari hamda yangi va samarali dori vositalarini kashf etishga olib kelganligini o'rgatdi. Xaseltinning ta'kidlashicha, agar bitta yangi inson geni kashf etilsa, zamonaviy biologiya texnikasi uning tabiiy funktsiyasini va potentsial tibbiy qo'llanilishini aniqlashga imkon beradi. Agar bu bitta gen uchun to'g'ri bo'lsa, unda nima uchun barcha inson genlari emas? Genlarni ajratish va tavsiflash bo'yicha mashaqqatli ishlarni yuqori darajada avtomatlashtirilgan asboblar bilan almashtirishga imkon beruvchi yangi vositalar ishlab chiqilgan bo'lib, ularning tuzilishi, to'qima va hujayralar joylashuvi va funktsional test natijalari bo'yicha ma'lumotlar saqlanib qolinib, ularga kirish oson. kompyuter texnologiyalari. U ushbu qarashlarni "Genomika, albatta, Genetika emas" degan bayonot bilan umumlashtirdi. Inson genomiga oid ilmiy yondashuv o'z ishi va sheriklarining ishi bilan tasdiqlanmaguncha, oxir-oqibat u ilmiy jamoatchilik tomonidan qabul qilindi.[140] Bugungi kunda inson genomi fanlari tomonidan kashf etilgan yondashuv yangi inson genlarini va boshqa turlarning genlarini topish va tavsiflash uchun ishlatiladigan asosiy vositalardan biridir.[140][141]

Inson genomi fanlarini genlarni kashf etish bo'yicha harakatlari muvaffaqiyatli bo'ldi. 1994 yil kuziga kelib Genomik tadqiqotlar instituti Inson genomi fanlari bilan ish olib bordi va barcha inson genlarining 90% dan ortig'ini qisman ketma-ket tahlil qilish bilan ajralib turdi. Ular xabarchi RNK sifatida ifodalangan to'qima va hujayralar haqida dastlabki ma'lumotlar va ularning normal va kasallik to'qimalarida ifodalanishiga oid ma'lumotlar mavjud edi.

Keyinchalik giyohvand moddalarni kashf etish ishlari boshlandi. Keyingi bir necha yil ichida Inson genomi fanlari genomik usullar yordamida kashf etilgan bir nechta yangi dori-darmonlarni klinik sinovlaridan o'tkazdi.Ularga terining o'sishining yangi omili - diabetik oshqozon yarasi va saraton terapiyasini keltirib chiqaradigan mukozitni davolash uchun, periferik oyoq-qo'l ishemiyasini davolash uchun qon tomir endotelial o'sish omilini, radioaktiv o'sish omilini - Keratinotsitlar o'sish faktor 2 kiradi. davolash uchun yodlangan B limfotsit stimulyatori (BLyS) ko'p miyeloma, Trail retseptorini taniydigan saraton kasalligini davolash uchun monoklonal antikor va BLyS (benlimumab, savdo nomi) bilan antagonizatsiya qiluvchi monoklonal antikor Benlysta ).

Benlysta 2010 yilda AQShning FDA tomonidan lupusni davolash uchun ma'qullangan. Benlysta tomonidan tasdiqlanganligi, giyohvand moddalarni kashf etishning yangi genomik usuli davolanishning oldingi urinishlariga qarshilik ko'rsatgan kasallikni davolashga olib keladi degan umidlarni bajardi. Bundan tashqari, inson genomi fanlari kuydirgi infektsiyalarini davolash va oldini olish uchun monoklonal antitel - "Kuydirgi" ni ishlab chiqdilar. Kuydirgi FDA tomonidan tasdiqlangan va hozirda AQSh hukumati tomonidan BioShield BARDA [Biomedical Advanced Research and Development Authority] qoidalariga binoan yig'ilgan.[142] Haseltine 2001 yildagi kuydirgi xurujidan so'ng darhol kuydirgiga antidot bo'yicha tadqiqotlar olib bordi.

2012 yil iyul oyida Glaxo SmithKline tomonidan Human Genome Sciences 3,6 milliard dollarga sotib olindi. Benlysta va Abthraxdan tashqari, sotib olish Glaxo SmithKline-ga Albiglutide-ga diabetni davolash uchun va Darapladib-ga koronar arteriya kasalligini davolash uchun eksklyuziv huquqlarni berdi, ikkalasi ham kech bosqichda o'tkazilgan klinik sinovlarda.

Rejenerativ tibbiyot

Garchi bu atama avvalgi tarixga ega bo'lgan bo'lsa-da, Haseltine "qayta tiklanadigan tibbiyot" atamasining keng qo'llanilishiga, ayniqsa, bugungi kunda qo'llanilgan ma'noga ega.[143] U odamni ajratish loyihasi bilan tanishtirilgandan so'ng embrional ildiz hujayralari va embrional jinsiy hujayralar Geron korporatsiyasi tadqiqotchilari bilan hamkorlikda Viskonsin-Medison universiteti va Jons Xopkins tibbiyot maktabi, Haseltine ushbu hujayralarning noyob qobiliyatini tan oldi farqlash inson tanasining barcha hujayra turlariga (pluripotensiya ) tarixda birinchi marta yangi turdagi regenerativ terapiya eshigini ochdi.[144][145] 1999 yilda Italiya Komo ko'li yaqinidagi konferentsiyada,[146] u bir nechta yangi texnologiyalar, shu jumladan, deb tushuntirdi gen terapiyasi, ildiz hujayrasi terapiya, to'qima muhandisligi va biomexanik protezlash - kollektiv ravishda yangi qobiliyatni ochdi va unga "regenerativ tibbiyot" atamasini bugungi kunda qanday ishlatilgan bo'lsa: "inson genlari, oqsillari va hujayralarini qayta o'stirish, tiklash yoki tiklash uchun ishlatadigan terapiyaga yondashuv" shikastlanish natijasida shikastlangan, kasallik tufayli zarar ko'rgan yoki vaqt o'tishi bilan eskirgan to'qimalarni mexanik almashtirishni ta'minlash "va" bugungi kunda samarali davolanib bo'lmaydigan kasalliklarni, shu jumladan qarish bilan bog'liq kasalliklarni davolash istiqbollarini taklif etadi. [147]

Haseltine birgalikda topishga kirishdi E-Biomed: Rejenerativ tibbiyot jurnali va yangi paydo bo'ladigan biotexnologiyani kengaytirishga yordam berish uchun Rejenerativ tibbiyot jamiyati. Haseltine yangi intizomning asosiy tuzilishini bayon etgan bir nechta maqolalarga mualliflik qildi.

COVID-19

Haseltine "podalar immuniteti" ni kutish strategiyasiga qarshi. "Mamlakatning 10 foizga yaqini yuqtirgan taqdirda, taxminan 216 ming kishi vafot etganini" hisobga olsak, - dedi u 2020 yil 14 oktyabrda televizion intervyusida - yuqtirishning 60-70 foizga erishish "ikki-olti million" degani. Amerikaliklar nafaqat bu yil, balki har yili vafot etdi ”. U shunday xulosaga keldi: "To'da immuniteti - bu ommaviy qotillikning yana bir so'zi".[148]

Davlat maslahatchisi

Haseltine has also served as a consultant to several governments. He was a member of the AIDS Executive Committee of the Milliy sog'liqni saqlash institutlari from 1986 to 1992 and served on the Council of the National Institute of Allergy and Infectious diseases from 1987 to 1991. It was during this time that he played a central role in crafting the US response to the HIV/AIDS epidemic. He was also an advisor to the President's Emergency Plan For AIDS Relief. From 1986 to 1990 he served as an informal advisor to the French government on HIV/AIDS. He has advised the governments of France, Germany, Italy, Hungary, India, and Singapore on biotechnology and economic development.

Xayriya

Haseltine began his career in philanthropy in 2004. He created two charitable foundations: The Foundation for Science and the Arts and ACCESS Health International, both 501C3 corporations. The Foundation for Medical Sciences and the Arts supports both biomedical research and the arts including the visual arts, music, opera and dance. A special focus of the foundation is the creation of works of art and music that interpret discoveries of biology and medicine.

Haseltine is a founder, chairman, and president of ACCESS Health International, an operating foundation devoted to improving access to high quality health worldwide, both in low and high income countries. This encompasses research, knowledge transfer, implementation support, and health technologies. ACCESS Health has offices in the United States, India, Singapore, the Philippines, mainland China, Hong Kong, Sweden, and the Netherlands. He is the author of the book "Affordable Excellence: The Singapore Healthcare Story: How to Create and Manage Sustainable Healthcare Systems "(74b) and of co-author of "Improving the Health of Mother and Child: Solutions from India ", "Modern Aging," available as an e-book on the ACCESS Health International website.,[149] and Aging with Dignity.[150]

Haseltine is an active supporter of several other not-for-profit organizations. In September 2015, he was elected as chairman of the board of the U.S.-China Health Summit. He is a member of the advisory board of the IE University, Madrid, a Lifetime Governor of the New York Academy of Sciences and the board of the New York Academy of Sciences. He is trustee of the Brookings Institution, the FXB Center for Health and Human Rights at the Harvard School of Public Health, the Lee Berger Trust for Paleoanthropology in South Africa, a member of the advisory council on Creativity and Innovation of the NYU-Shanghai University, a member of the Council on Foreign Relations, a member of the Board of AID for AIDS International and a chairman of the International China Ageing Industry Association and the US-China Health Summit. He is a trustee of the Lee R. Berger Foundation for Exploration Trust of South Africa.

He is a patron of the Metropolitan Opera, a patron of the Metropolitan Museum of Art, the Guggenheim Museum, the Museum of Modern Art, and a member of the Patron's Circle of the Asia Society. He is a Member of board of directors of the Young Concert Artists, the Youth Orchestra of the Americas, and the China Arts Foundation and a founder of the new Whitney Museum of American Art.

Kitoblar

Affordable Excellence: the Singapore Healthcare Story; William A Haseltine. Brookings Institution Press, National University of Singapore Press. (2013)

Improving the Health of Mother and Child: Solutions from India; Priya Anant, Prabal Vikram Singh, Sofi Bergkvist, William A. Haseltine & Anita George. ACCESS Health International www.accessh.org. (2014)

Modern Aging: A Practical Guide for Developers, Entrepreneurs, and Startups in the Silver Market; Edited by Sofia Widén, Stephanie Treschow, and William A. Haseltine. Amazon.com, ACCESS Health International www.accessh.org. (2015)

Aging with Dignity: Innovation and Challenge is Sweden-The Voice of Care Professionals; Sofia Widen and William A. Haseltine, Nordic Academic Press. ISBN  978-91 88168-90-0. (2017)

Every Second Counts: Saving Two Million Lives. India’s Emergency response System. The EMRI Story; William A Haseltine. Thethys Press India, The Brooking Institution Press. ISBN  978-93-83125-15-9. (2017)

Voices in Dementia Care; Anna Dirksen and William A Haseltine, Thethys Press India. ISBN  978-93-83125-16-6. (2018)

Aging Well; (2019)

World Class. Adversity, Transformation and Success and NYU Langone Health; (2019)


A Family Guide to Covid (2020 yil 30-iyun)

Adabiyotlar

  1. ^ http://www.saworldview.com/worldview-100/the-worldview-100/
  2. ^ Shirk, J; Haseltine WA; Pimental GC (1965). "Sinton Bands Evidence for Deuterated Water on Mars". Ilm-fan. 147 (3653): 48–49. Bibcode:1965Sci...147...48S. doi:10.1126/science.147.3653.48. PMID  17799778. S2CID  36085745.
  3. ^ Stephanson, JC; Haseltine WA; Moore CB (1967). "Atmospheric Absorption of CO2 Laser Radiation". Amaliy fizika xatlari. 11 (5): 164–166. doi:10.1063/1.1755081.
  4. ^ Haseltine, WA (1972). "In Vitro Transcription of Escherichia coli Ribosomal RNA Genes". Tabiat. 235 (5337): 329–333. doi:10.1038/235329a0. PMID  4551521. S2CID  4226011.
  5. ^ Haseltine, WA; Block R; Gilbert W; Weber K (1972). "MSI and MSII Made on the Ribosome in Idling Step of Protein Synthesis". Tabiat. 238 (5364): 381–384. Bibcode:1972Natur.238..381H. doi:10.1038/238381a0. PMID  4559580. S2CID  4251028.
  6. ^ Haseltine, WA; Block R (1974). "Synthesis of Guanosine Tetra- and Penta-phosphate Requires the Presence of Codon Specific Uncharged Transfer Ribonucleic Acid in the Acceptor Site of Ribosomes". Milliy fanlar akademiyasi materiallari. 70 (5): 1564–1568. Bibcode:1973PNAS ... 70.1564H. doi:10.1073 / pnas.70.5.1564. PMC  433543. PMID  4576025.
  7. ^ Block, R; Haseltine WA (1973). "Thermolobility of the Stringent Factor in rel Mutants of Escherichia coli". Molekulyar biologiya jurnali. 77 (4): 625–629. doi:10.1016/0022-2836(73)90228-3. PMID  4579452.
  8. ^ Block, R; Haseltine WA (1974). "Purification and Properties of Stringent Factor". Biologik kimyo jurnali. 250 (4): 1212–1217. PMID  163249.
  9. ^ Cooke, Robert C; William A Haseltine; Arthur Galston. "Deliberate Destruction of the Environment: What Have we Done to Vietnam?". Yangi respublika. 162 (2): 18.
  10. ^ Panet, A; Haseltine WA; Baltimore D; Peters G; Harada F; Dahlberg S (1975). "Specific Binding of Tryptophan Transfer RNA to Avian Myeloblastosis Virus Reverse Transcriptase". Milliy fanlar akademiyasi materiallari. 72 (7): 2525–2539. doi:10.1073/pnas.72.7.2535. PMC  432803. PMID  52156.
  11. ^ Haseltine, WA; Baltimore D (1976). "Size of Murine RNA Tumor Virus-specific Nuclear RNA Molecules". Virusologiya jurnali. 19 (2): 331–340. doi:10.1128/JVI.19.2.331-337.1976. PMC  354870. PMID  183009.
  12. ^ Haseltine, WA; Kleid D; Panet A; Rothenberg E; Baltimore D (1976). "Ordered Transcription of RNA Tumor Viruses by Reverse Transcriptase In Vitro". Molekulyar biologiya jurnali. 106 (1): 109–131. doi:10.1016/0022-2836(76)90303-x. PMID  61277.
  13. ^ Rose, J; Haseltine WA; Baltimore D (1976). "5'-Terminus of Moloney Murine Leukemia Virus 35s RNA is m7G5ppp5'GmpCp". Virusologiya jurnali. 20 (1): 324–329. doi:10.1128/JVI.20.1.324-329.1976. PMC  354993. PMID  185415.
  14. ^ Peters, G; Harada F; Dahlberg JE; Haseltine WA; Panet A; Baltimore D (1977). "Identification of RNA Primer of DNA Synthesis of Moloney Murine Leukemia Virus". Virusologiya jurnali. 21 (3): 1031–41. doi:10.1128/JVI.21.3.1031-1041.1977. PMC  515643. PMID  66325.
  15. ^ Freisen, JD; Fiil NP, Parker JM, Haseltine, WA; Parker, J. M.; Haseltine, W. A. (1974). "A New Relaxed Mutant of Escherichia coli with an altered 50s Ribosomal Subunit". Milliy fanlar akademiyasi materiallari. 71 (9): 3465–3469. Bibcode:1974PNAS...71.3465F. doi:10.1073/pnas.71.9.3465. PMC  433794. PMID  4610577.CS1 maint: bir nechta ism: mualliflar ro'yxati (havola)
  16. ^ Haseltine, WA; Maxam A; Gilbert W (1977). "The Rous Sarcoma Virus Genome is Terminally Redundant the 5' Sequence". Milliy fanlar akademiyasi materiallari. 74 (3): 989–993. Bibcode:1977PNAS...74..989H. doi:10.1073/pnas.74.3.989. PMC  430558. PMID  66683.
  17. ^ Coffin, J; Haseltine WA (1977). "Terminal Redundancy and the Origin of Replication of Rous Sarcoma Virus RNA". Milliy fanlar akademiyasi materiallari. 74 (5): 1908–1912. Bibcode:1977PNAS...74.1908C. doi:10.1073/pnas.74.5.1908. PMC  431041. PMID  68472.
  18. ^ Haseltine, WA; Panet A; Smoler D; Baltimore D; Peters G; Harada F; Dahlberg J (1977). "Interaction of AMV Reverse Transcriptase and tRNAtrp". Biokimyo. 16 (16): 3625–3632. doi:10.1021/bi00635a019. PMID  70221.
  19. ^ Coffin, J; Haseltine WA (1977). "Nucleotide Sequence of Rous Sarcoma Virus RNA at the Initiation Site of DNA Synthesis". Molekulyar biologiya jurnali. 117 (3): 805–814. doi:10.1016/0022-2836(77)90071-7. PMID  204788.
  20. ^ Tobut, JM; Hageman RC; Maxam AM; Haseltine WA (1978). "Structure of the Genome of Moloney Murine Leukemia Virus: A Terminally Redundant Sequence". Hujayra. 13 (4): 761–773. doi:10.1016/0092-8674(78)90226-x. PMID  657274. S2CID  9682663.
  21. ^ Haseltine, WA; Coffin JM; Hageman TC (1979). "Structure of Product of the Moloney Murine Leukemia Virus Endogenous DNA Polymerase Reaction". Virusologiya jurnali. 30 (1): 375–383. doi:10.1128/JVI.30.1.375-383.1979. PMC  353331. PMID  90161.
  22. ^ Pedersen, FS; Buchhagan DL; Chen CY; Hays EF; Haseltine WA (1980). "Characterization of Virus Produced by a Lymphoma Induced by Inoculation of AKR MCF-247 Virus". Virusologiya jurnali. 35 (1): 211–218. doi:10.1128/JVI.35.1.211-218.1980. PMC  288797. PMID  6251269.
  23. ^ Buchhagan, DL; Pedersen FS; Crowther RL; Haseltine WA (1980). "Most Sequence Differences Between the Genomes of the AKV Virus and a Leukemogenic Gross A Virus Passaged In Vitro are located Near the 3' Terminus". Milliy fanlar akademiyasi materiallari. 77 (7): 4359–4363. Bibcode:1980PNAS...77.4359B. doi:10.1073/pnas.77.7.4359. PMC  349834. PMID  6254022.
  24. ^ Pedersen, FS; Crowther RL; Tenney DY; Reimold AM; Haseltine WA (1981). "Novel Leukemogenic Retroviruses Isolated from Cell Line Derived from Spontaneous AKR Tumor". Tabiat. 292 (5819): 167–170. doi:10.1038/292167a0. PMID  6264322. S2CID  4326931.
  25. ^ Pedersen, FS; Crowther RL; Hays EF; Nowinski RC; Haseltine WA (1982). "Structure of Retroviral RNAs Produced by Cell Lines Derived from Spontaneous Lymphomas of AKR Mice". Virusologiya jurnali. 41 (1): 18–29. doi:10.1128/JVI.41.1.18-29.1982. PMC  256722. PMID  7086955.
  26. ^ Lenz, J; Crowther R; Straceski A; Haseltine WA (1982). "Nucleotide Sequences of the Akv env Gene". Virusologiya jurnali. 42 (2): 519–529. doi:10.1128/JVI.42.2.519-529.1982. PMC  256878. PMID  6283170.
  27. ^ Lenz, J; Crowther R; Klimenko S; Haseltine WA (1982). "Molecular Cloning of a Highly Leukemogenic, Ecotropic Retrovirus from an AKR Mouse". Virusologiya jurnali. 43 (3): 943–951. doi:10.1128/JVI.43.3.943-951.1982. PMC  256205. PMID  6292472.
  28. ^ Lenz, J; Haseltine WA (1983). "Localization of the Leukemogenic Determinants of SL3-3, an Ecotropic, XC-Positive, Murine Leukemia Virus of AKR Origin". Virusologiya jurnali. 47 (2): 317–328. doi:10.1128/JVI.47.2.317-328.1983. PMC  255263. PMID  6312068.
  29. ^ Lenz, J; Celander D; Crowther RL; Patarca R; Perkins DW; Sheldon A; Haseltine WA (1984). "Enhancer Sequences that Determine Leukemogenicity of a Murine Retrovirus". Tabiat. 308 (5958): 467–470. doi:10.1038/308467a0. PMID  6323995. S2CID  4263098.
  30. ^ Celander, D; Haseltine WA (1984). "Tissue Specific Preference as a Determinant of Cell Tropism and Leukemogenic Potential of Murine Retroviruses". Tabiat. 312 (5990): 159–162. Bibcode:1984Natur.312..159C. doi:10.1038/312159a0. PMID  6095084. S2CID  4230311.
  31. ^ Rosen, CR; Haseltine WA; Lenz J; Ruprecht R; Cloyd M (1985). "Tissue Selectivity of Murine Leukemia Virus (MULV) Infection is Determined by LTR Sequences". Virusologiya jurnali. 55 (3): 862–866. doi:10.1128/JVI.55.3.862-866.1985. PMC  255076. PMID  2991605.
  32. ^ Celander, D; Haseltine WA (1987). "Glucocorticoid Regulation of Murine Leukemia Virus Transcription Elements Is Specified by Determinants within the Viral Enhancer region". Virusologiya jurnali. 61 (2): 266–275. doi:10.1128/JVI.61.2.269-275.1987. PMC  253946. PMID  3027359.
  33. ^ D'Andrea, AD; Haseltine WA (1978). "Sequence Cleavage of DNA by the Anti-tumor Antibiotics Neocarzinostatin and Bleomycin". Milliy fanlar akademiyasi materiallari. 75 (8): 3608–3612. Bibcode:1978PNAS...75.3608D. doi:10.1073/pnas.75.8.3608. PMC  392834. PMID  80799.
  34. ^ D'Andrea, AD; Haseltine WA (1978). "Modification of DNA by Aflatoxin B1 Creates Alkali-Labile Lesions in DNA at Positions of Guanine and Adenine". Milliy fanlar akademiyasi materiallari. 75 (9): 4120–4124. Bibcode:1978PNAS...75.4120D. doi:10.1073/pnas.75.9.4120. PMC  336063. PMID  30083.
  35. ^ Haseltine, WA; Lo KM; D'Andrea AD (1980). "Preferred Sites of Strand Scission in DNA Modified by anti-Diol Epoxide of Benzo(a)pyrene". Ilm-fan. 209 (4459): 929–931. Bibcode:1980Sci...209..929H. doi:10.1126/science.7403858. PMID  7403858.
  36. ^ Gordon, LK; Haseltine WA (1980). "Comparison of the Cleavage of Pyrimidine Dimers by the Bacteriophage T4 and M. luteus UV-Specific Endonucleases". Biologik kimyo jurnali. 255 (24): 12047–12050. PMID  6254991.
  37. ^ Grunberg, SM; Haseltine WA (1980). "Use of an Indicator Sequence of Human DNA to Study DNA Damage by Methylbis(2-chloreothyl)amine". Milliy fanlar akademiyasi materiallari. 77 (11): 6546–6550. Bibcode:1980PNAS...77.6546G. doi:10.1073/pnas.77.11.6546. PMC  350322. PMID  6935667.
  38. ^ Martin, RF; Haseltine WA (1981). "Range of Radiochemical Damage to DNA with Decay of Iodine 125". Ilm-fan. 213 (4510): 896–898. Bibcode:1981Sci...213..896M. doi:10.1126/science.7256283. PMID  7256283.
  39. ^ Berlin, V; Haseltine WA (1981). "Reduction of Adriamycin to a Semiquinone Fee Radical by NAHPH Cytochrome P-450 Reductase Produces DNA Cleavage in a Reaction Mediated by Molecular Oxygen". Biologik kimyo jurnali. 256 (10): 4747–4756. PMID  6262301.
  40. ^ Lipke, JA; Gordon LK, Brash, DE, Haseltine WA; Brash, D. E.; Haseltine, W. A. (1981). "Distribution of Ultraviolet Light Induced Damage in a Defined Sequence of Human DNA: Detection of Alkaline Sensitive Lesions at Pyrimidine-Nucleoside-Cytidine Sequences". Milliy fanlar akademiyasi materiallari. 78 (6): 3388–3392. Bibcode:1981PNAS...78.3388L. doi:10.1073/pnas.78.6.3388. PMC  319573. PMID  6943547.CS1 maint: bir nechta ism: mualliflar ro'yxati (havola)
  41. ^ Royer-Pokora, B; Gordon LK; Haseltine WA (1982). "Use of ExonucleaseIII to Determine the Site of Stable Lesions in Defined Sequences of DNA; The Cyclobutane Pyrimidine Dimer and cis and trans Dichloradiammine Platinum II Examples". Nuklein kislotalarni tadqiq qilish. 9 (18): 4595–4609. doi:10.1093/nar/9.18.4595. PMC  327461. PMID  6272211.
  42. ^ Kross, J; Henner WD; Hecht SM; Haseltine WA (1982). "Specificity of Deoxyribonucleic Acid Cleavage by Bleomycin, Phleomycin and Tallysomycin". Biokimyo. 21 (18): 4310–4318. doi:10.1021/bi00261a021. PMID  6181807.
  43. ^ Kross, J; Henner WD; Haseltine WA; Rodriguez L; Levin M; Hecht SM (1982). "Structural Basis for the DNA Affinity of Bleomycins". Biokimyo. 21 (15): 3711–3721. doi:10.1021/bi00258a029. PMID  6180763.
  44. ^ Henner, WD; Grunberg SM; Haseltine WA (1982). "Sites and Structure of Gamma Radiation Induced DNA Strand Breaks". Biologik kimyo jurnali. 257 (19): 11750–11754. PMID  7118909.
  45. ^ Henner, WD; Grunberg SM; Haseltine WA (1983). "Enzyme Action at 3' Termini of Ionizing Radiation-induced DNA Strand Breaks". Biologik kimyo jurnali. 258 (24): 15198–15205. PMID  6361028.
  46. ^ Frei, E; Rosowsky A; Wright JE; Cucchi CA; Lippke JA; Ervin TJ; Jolivet J; Haseltine WA (1984). "Development of Methotrexate Resistance in a Human Squamous Cell Carcinoma of the Head and Neck in Culture". Milliy fanlar akademiyasi materiallari. 81 (9): 2873–2877. Bibcode:1984PNAS...81.2873F. doi:10.1073/pnas.81.9.2873. PMC  345174. PMID  6201865.
  47. ^ Sage, E; Haseltine WA (1984). "High Ratio of Alkali Sensitive Lesions to Total DNA Modification Induced by Benso(a)pyrene diol epoxide". Biologik kimyo jurnali. 259 (17): 11098–11102. PMID  6432792.
  48. ^ Janicek, MF; Haseltine WA; Henner WD (1985). "Malondialdehyde Precursors in gamma-irradiated DNA, deoxynucleotides and deoxynucleosides". Nuklein kislotalarni tadqiq qilish. 13 (24): 9011–9029. doi:10.1093/nar/13.24.9011. PMC  318968. PMID  4080556.
  49. ^ Haseltine, WA; Gordon LK; Lindan CP; Grafstrom RH; Shaper NL; Grossman L (1980). "Cleavage of Pyrimidine Dimers in Specific DNA Sequences by a Pyrimidine Dimer DNA-Glycosylase of M.luteus". Tabiat. 285 (5767): 634–641. Bibcode:1980Natur.285..634H. doi:10.1038/285634a0. PMID  6248789. S2CID  2811671.
  50. ^ Gordon, LK; Haseltine WA (1982). "Quantitation of Cyclobutane Pyrimidine Dimer Formation in Double and Single Stranded DNA Fragments of Defined Sequences". Radiatsion tadqiqotlar. 89 (1): 99–112. doi:10.2307/3575688. JSTOR  3575688. PMID  7063608.
  51. ^ Henner, WD; Rodriguez LO; Hecht SM; Haseltine WA (1983). "Gamma Ray Induced Deoxyribonucleic Acid Strand Breaks: 3' Glycolate Termini". Biologik kimyo jurnali. 258 (2): 711–713. PMID  6822504.
  52. ^ Royer-Pokora, B; Pedersen W; Haseltine WA (1984). "Biological and Biochemical Characterization of an SV40 Transformed Xeroderma Pigmentosum Cell Line". Eksperimental hujayra tadqiqotlari. 151 (2): 408–420. doi:10.1016/0014-4827(84)90391-4. PMID  6323201.
  53. ^ DeLuca, D; Doetsch PW; Haseltine WA (1984). "Construction of a Mammalian Expression Vector for the E. coli uvrA, b, and C Genes". Plazmid. 11 (3): 253–259. doi:10.1016/0147-619x(84)90032-5. PMID  6087393.
  54. ^ Royer-Pokora, B; Haseltine WA (1984). "Isolation of UV Resistant Revertants from a Xeroderma Pigmentosum Complementation Group A Cell Line". Tabiat. 311 (5984): 390–392. Bibcode:1984Natur.311..390R. doi:10.1038/311390a0. PMID  6090936. S2CID  4361696.
  55. ^ Brash, DE; Haseltine WA (1985). "Photoreactivation of E.coli Reverses umuC Induction by Ultraviolet Light". Bakteriologiya jurnali. 163 (2): 460–463. doi:10.1128/JB.163.2.460-463.1985. PMC  219144. PMID  2991189.
  56. ^ Doetsch, PW; Helland D; Haseltine WA (1986). "Mechanism of Action of a Mammalian DNA Repairs Endonuclease". Biokimyo. 25 (8): 2212–2220. doi:10.1021/bi00356a054. PMID  2423122.
  57. ^ Helland, D; Doetsch PW; Haseltine WA (1986). "Substrate Specificity of a Mammalian DNA Repair Endonuclease that Recognizes Oxidative Base Damage". Molekulyar va uyali biologiya. 6 (6): 1983–1990. doi:10.1128/mcb.6.6.1983. PMC  367737. PMID  3537712.
  58. ^ Sutherland, BM; Feng NI; Oliviera OM; Cairrachi G; Brash DE; Haseltine WA; Lyuis RJ; Hanawalt PC. (1986). "Substrate Range of the 40 000-Dalton DNA- Photoreactivating Enzyme from Escherichia coli". Biokimyo. 25 (3): 681–687. doi:10.1021/bi00351a026. PMID  3513832.
  59. ^ Gordon, LK; Haseltine WA (1981). "Early Steps of Excision Repair of Cyclobutane Pyrimidine Dimers by the Micrococcus Luteus Endonuclease; A Three Step Incision Model". Biologik kimyo jurnali. 256: 6608–6616. PMID  6263931.
  60. ^ Franklin, WA; Haseltine WA (1984). "Removal of UV Light-induced Pyrimidine-Pyrimidone (6-4) Products from Escherichia coli DNA Requires the uvrA, uvrB, and uvrC Gene Products". Milliy fanlar akademiyasi materiallari. 81 (12): 3821–3824. Bibcode:1984PNAS...81.3821F. doi:10.1073/pnas.81.12.3821. PMC  345312. PMID  6374666.
  61. ^ Chan, GL; Doetsch PW; Haseltine WA (1985). "Cyclobutane Pyrimidine Dimers (6-4) Photo Product Block Polymerization by DNA Polymerase". Biokimyo. 24 (21): 5723–5728. doi:10.1021/bi00342a006. PMID  4084488.
  62. ^ Umlas, ME; Franklin WA; Chan GL; Haseltine WA (1985). "Ultraviolet Light Irradiation of Defined-Sequenced DNA Under Conditions of Chemical Photosensitization". Fotokimyo va fotobiologiya. 42 (3): 265–273. doi:10.1111/j.1751-1097.1985.tb08941.x. PMID  3903794.
  63. ^ Brash, DE; Franklin WA; Sancar GB; Sancar A; Haseltine WA (1985). "E. coli DNA Photolyase Reverses Cyclobutane Pyrimidine Dimers but not Pyrimidine-Pyrimidone (6-4) Photoproducts". Biologik kimyo jurnali. 260 (21): 11438–11441. PMID  3900062.
  64. ^ Franklin, WA; Haseltine WA (1986). "The Role of the (6-4) Photoproduct in Ultraviolet Light-Induced Transition Mutations in E.coli". Mutatsion tadqiqotlar. 319 (1): 555–559. doi:10.1016/0167-8817(86)90002-7. PMID  3001515.
  65. ^ Chan, GL; Peak MJ, Peak JG, Haseltine, WA; Peak, Jennifer G.; Haseltine, William A. (1986). "Action Spectrum for the Formation of Endonuclease-sensitive sites and (6-4) Photoproducts Induced in a DNA by Ultraviolet Radiation". Journal of Radiation Biology. 50 (4): 641–648. doi:10.1080/09553008614551041. PMID  3489687.CS1 maint: bir nechta ism: mualliflar ro'yxati (havola)
  66. ^ Reitz, MS Jr; Wong-Staal F; Haseltine WA; Kleid DG; Trainer CD; Gallagher RE; Gallo RC (1979). "Gibbon Ape Leukemia Virus Hall's Island: New Strain of Gibbon Ape Leukemia Virus". Virusologiya jurnali. 29 (1): 395–400. doi:10.1128 / JVI.29.1.395-400.1979. PMC  353141. PMID  219232.
  67. ^ Sahagan, BG; Haseltine WA (1979). "Structural Analysis of the Genomes of Woolly Monkey and Gibbon Ape Leukosis Viruses". Virusologiya jurnali. 31 (3): 657–667. doi:10.1128/JVI.31.3.657-667.1979. PMC  353494. PMID  229247.
  68. ^ Rosenberg, ZR; Haseltine WA (1980). "A Transfection Assay for Transformation by Feline Sarcoma Virus Proviral DNA". Virusologiya. 102 (1): 240–244. doi:10.1016/0042-6822(80)90089-6. PMID  6245507.
  69. ^ Sahagen, BG; Haseltine WA (1980). "Relationship of Retroviruses Isolated from Leukemia Tissues to the Woolly-Monkey-Gibbon Ape Leukemia Viruses". Virusologiya jurnali. 34 (2): 390–401. doi:10.1128/JVI.34.2.390-401.1980. PMC  288717. PMID  6246270.
  70. ^ Rosenberg, ZF; Pedersen FS; Haseltine WA (1980). "Comparative Analysis of the Genomes of Feline Leukemia Viruses". Virusologiya jurnali. 35 (2): 542–546. doi:10.1128/JVI.35.2.542-546.1980. PMC  288839. PMID  6255191.
  71. ^ Clements, JE; Pedersen FS; Narayan O; Haseltine WA (1980). "Genomic Changes Associated with Antigenic Variation of Visna Virus during Persistent Infection". Milliy fanlar akademiyasi materiallari. 77 (8): 4454–4458. Bibcode:1980PNAS...77.4454C. doi:10.1073/pnas.77.8.4454. PMC  349862. PMID  6254026.
  72. ^ Rosenberg, ZF; Crowther RL; Essex M; Jarrett O; Haseltine WA (1981). "Isolation Via Transfection of Feline Leukemia Viruses from DNA of Naturally Occurring Feline Lymphomas". Virusologiya. 115 (1): 203–210. doi:10.1016/0042-6822(81)90102-1. PMID  6270898.
  73. ^ Rosenberg, ZF; Sahagan BG; Snyder HW; Worley MB; Essex M; Haseltine WA (1981). "Biochemical characterization of cells transformed via transfection by feline sarcoma virus proviral DNA". Virusologiya jurnali. 38 (2): 782–788. doi:10.1128/JVI.38.2.782-788.1981. PMC  171209. PMID  6264144.
  74. ^ Rosenberg, ZF; Sahagen BG; Worley MB; Essex M; Haseltine WA (1981). "Transformation with Subgenomic Fragments of Feline Sarcoma Virus Proviral DNA". Virusologiya. 112 (2): 496–504. doi:10.1016/0042-6822(81)90297-x. PMID  6266138.
  75. ^ Trus, MD; Sodroski JG; Haseltine WA (1982). "Isolation and Characterization of a Human Locus Homologous to the Transforming Gene (v-fes) of Feline Sarcoma Virus". Biologik kimyo jurnali. 257 (6): 2730–2733. PMID  6277911.
  76. ^ Sodroski, JG; Goh WC; Haseltine WA (1984). "Transforming Potential of the Human c-fps/fes Locus". Milliy fanlar akademiyasi materiallari. 81 (10): 3039–3043. Bibcode:1984PNAS...81.3039S. doi:10.1073/pnas.81.10.3039. PMC  345216. PMID  6328490.
  77. ^ Sodroski, JG; Rosen C; Haseltine WA (1984). "Trans-acting Transcriptional Activation of the Long Terminal Repeat of Human T Lymphotropic Viruses in Infected Cells". Ilm-fan. 225 (4660): 381–385. Bibcode:1984Sci...225..381S. doi:10.1126/science.6330891. PMID  6330891.
  78. ^ Haseltine, WA; Sodroski JG; Patarca R; Briggs D; Perkins D; Wong-Staal F (1984). "Structure of the 3' Terminal Region of Type II Human T Lymphotropic Virus: Evidence for a New Coding Region". Ilm-fan. 225 (4660): 419–421. Bibcode:1984Sci...225..419H. doi:10.1126/science.6330894. PMID  6330894.
  79. ^ Josephs, JF; Wong Staal F; Manzari V; Gallo RC; Sodroski JG; Trus M; Perkins D; Patarca R; Haseltine WA (1984). "Long Terminal Repeat Structure of an American Isolate of Human T Cell Leukemia Virus". Virusologiya. 139 (2): 340–345. doi:10.1016/0042-6822(84)90379-9. PMID  6097028.
  80. ^ Rosen, CA; Sodroski JG; Kettman R; Burny A; Haseltine WA (1985). "Trans-activation of the Bovine Leukemia Virus Long Terminal Repeat". Ilm-fan. 227 (4684): 320–322. Bibcode:1985Sci...227..320R. doi:10.1126/science.2981432. PMID  2981432.
  81. ^ Sodroski, JG; Rosen CR; Goh WC; Haseltine WA (1985). "The Human T-Cell Leukemia Virus x-lor Region Encodes a Transcriptional Activator Protein". Ilm-fan. 228 (4706): 1430–1434. Bibcode:1985Sci...228.1430S. doi:10.1126/science.2990028. PMID  2990028.
  82. ^ Goh, WC; Sodroski JG; Rosen CR; Haseltine WA (1985). "Expression of the x-lor Gene in E.coli". Virusologiya jurnali. 55 (2): 497–499. doi:10.1128/JVI.55.2.497-499.1985. PMC  254960. PMID  2991573.
  83. ^ Sodroski, JG; Goh WC; Rosen CR; Salohiddin SZ; Aldovini A; Franchini G; Wong-Staal F; Gallo RC; Sugamura K; Haseltine WA (1985). "Trans-Activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-lor protein". Virusologiya jurnali. 55 (3): 831–835. doi:10.1128/JVI.55.3.831-835.1985. PMC  255069. PMID  2991599.
  84. ^ a b Rosen, CR; Sodroski JG; Campbell K; Haseltine WA (1986). "Construction of Recombinant Retroviruses that Express the Human T Cell Leukemia Virus Type II and Human T Cell Leukemia Virus Type III Transactivator". Virusologiya jurnali. 57 (1): 379–384. doi:10.1128/JVI.57.1.379-384.1986. PMC  252741. PMID  3001360.
  85. ^ Greene, WC; Leonard WJ; Wano J; Svetlik PB; Peffer NJ; Sodroski JG; Rosen CA; Goh WC; Haseltine WA (1986). "The Transactivator Gene of Human T Lymphotropic Virus Type II (HTLV-II) Induces Interleukin-2 Receptor and Interleukin-2 Gene Expression". Ilm-fan. 232 (4752): 877–880. doi:10.1126/science.3010456. PMID  3010456.
  86. ^ Rosen, CA; Sodroski JG; Willems L; Kettmann R; Campbell K; Zaya R; Burny A; Haseltine WA (1986). "The 3' region of bovine leukemia virus genome encodes a trans-activator protein" (PDF). EMBO jurnali. 5 (10): 2585–2589. doi:10.1002/j.1460-2075.1986.tb04538.x. PMC  1167156. PMID  3023049.
  87. ^ Grassmann, R; Dengler C; Muller-Fleckenstein I; Fleckenstein B; McGuire K; Dokhelar M; Sodroski JG; Haseltine WA (1989). "Transformation to Continuous Growth of Primary Human Lymphocytes by HTLV-1 X Region Genes Transduced by a Herpesvirus Saimiri Vector". Milliy fanlar akademiyasi materiallari. 86 (9): 3351–3355. Bibcode:1989PNAS...86.3351G. doi:10.1073/pnas.86.9.3351. PMC  287130. PMID  2541443.
  88. ^ a b Langhoff, E; Terwilliger E; Bos H; Kalland K; Poznansky M; Sodroski J; Haseltine W (1991). "Prolific Replication of HIV-1 in Primary Dendritic Cell Cultures". Milliy fanlar akademiyasi materiallari. 88 (18): 7998–8002. Bibcode:1991PNAS...88.7998L. doi:10.1073/pnas.88.18.7998. PMC  52432. PMID  1910172.
  89. ^ Fumento, Michael (1990). The Myth of Heterosexual AIDS: How a Tragedy Has Been Exploited by the Media and Partisan Politics. Asosiy kitoblar.
  90. ^ Casselman, Anne (2005). "20 Years Ago in Discover: Misunderstanding AIDS". Kashf eting. 26 (4): 13.
  91. ^ Ratner, L; Haseltine WA, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Antoni Rafalski J, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F; Patarka, Roberto; Livak, Kennet J.; Starcich, Bruno; Xosefs, Stiven F.; Doran, Ellen R.; Rafalski, J. Antoni; Whitehorn, Erik A.; Baumeister, Kirk; Ivanoff, Lucinda; Petteway, Stephen R.; Pearson, Mark L.; Lautenberger, James A.; Papas, Takis S.; Ghrayeb, John; Chang, Nancy T.; Gallo, Robert C.; Wong-Staal, Flossie (1985). "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III". Tabiat. 313 (6000): 277–284. Bibcode:1985Natur.313..277R. doi:10.1038 / 313277a0. PMID  2578615. S2CID  4316242.CS1 maint: bir nechta ism: mualliflar ro'yxati (havola)
  92. ^ Haseltine, WA; Sodroski J; Terwilliger E (1989). "Replication and Pathogenesis of HIV-1 Retrovirus Relevant to Drug Design. IN: Retroviruses and Disease". Proceedings of International Symposium on Medical Virology: 159–181.
  93. ^ Haseltine, WA (1988). A Rational Approach To Chemotherapy of AIDS. IN: HIV and Other Highly Pathogenic Viruses. 25-32 betlar.
  94. ^ Haseltine, WA (1988). "Replication and Pathogenesis of the AIDS Virus. (Plenary Lecture presented at the IVth International Conference on AIDS, Stockholm, Sweden)". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 1 (3): 217–240. PMID  3063806.
  95. ^ Haseltine, WA (April 1989). "Current and Future Prospects for Anti-Viral AIDS Drug Development". Proceedings of the Symposium Biotechnology and the AIDS Challenge in Massachusetts: A Symposium Report: 87–89.
  96. ^ Haseltine, WA (1989). "Prospects for Medical Control of the AIDS Epidemic. In: Daedalus: Living with AIDS, Part II". Amerika San'at va Fanlar Akademiyasining jurnali. 118: 1–21.
  97. ^ Terwilliger, EF; Sodroski JG; Haseltine WA (1989). "Mechanisms of Infectivity and Replication of HIV-1 and Implications for Therapy". Shoshilinch tibbiyot yilnomalari. 19 (3): 233–241. doi:10.1016/s0196-0644(05)82036-0. PMID  2178499.
  98. ^ Haseltine, WA (1989). "Development of Antiviral Drugs for the Treatments of AIDS: Strategies & Prospects". Journal of Acquired Deficiency Syndromes. 2: 311.
  99. ^ Haseltine, WA (1992). "Molecular Biology of the AIDS Virus: Ten Years of Discovery – Hope for the Future". Science Challenging AIDS: 71–106.
  100. ^ Sodroski, JG; Rosen CR; Wong-Staal F; Popovic M; Arya S; Gallo RC; Haseltine WA; Haseltine, W. (1985). "Trans-acting Transcriptional Activation of the Long Terminal Repeat of Human T Cell Leukemia Virus Type III (HTLV-III)". Ilm-fan. 227 (4683): 171–173. Bibcode:1985Sci...227..171S. doi:10.1126/science.2981427. PMID  2981427.
  101. ^ Sodroski, JG; Patarca R; Rosen CR; Wong-Staal F; Haseltine WA (1985). "Location of the Trans-activating Region on the Genome of Human T-Cell Lymphotropic Virus Type III". Ilm-fan. 229 (4708): 74–77. Bibcode:1985Sci...229...74S. doi:10.1126/science.2990041. PMID  2990041.
  102. ^ Rosen, CR; Sodroski, JG, Haseltine WA. (1985). "Location of Cis-Acting Regulatory Sequences in the Human T Cell Lymphotropic Virus Type III (HTLV-III/LAV) Long Terminal Repeat". Hujayra. 41 (3): 813–23. doi:10.1016/S0092-8674(85)80062-3. PMID  2988790. S2CID  27556762.CS1 maint: bir nechta ism: mualliflar ro'yxati (havola)
  103. ^ Rosen, CA; Sodroski JG; Goh WC; Dayton A; Lippke J; Haseltine WA (1986). "Post Transcriptional Regulation Accounts for the trans-activation of the Human T Lymphotropic Viruses Type III (HTLV-III/LAV)". Tabiat. 319 (6054): 555–559. Bibcode:1986Natur.319..555R. doi:10.1038/319555a0. PMID  3003584. S2CID  38771898.
  104. ^ Patarca, R; Haseltine WA (1987). "HIV tat and tar". OITS tadqiqotlari va odamning retroviruslari. 3 (1): 1–2. doi:10.1089/aid.1987.3.1. PMID  3650098.
  105. ^ Sodroski, JG; Goh WC; Rosen CA; Dayton AI; Terwilliger E; Haseltine WA (1986). "A Second post-Transcriptional Trans-activator Gene required for HTLV III Replication". Tabiat. 321 (6068): 412–417. Bibcode:1986 yil Nat.221..412S. doi:10.1038 / 321412a0. PMID  3012355. S2CID  4306352.
  106. ^ Goh, WC; Sodroski JG; Rosen CA; Haseltine WA (1987). "Expression of the art Gene Protein of HTLV-III/LAV in Bacteria". Virusologiya jurnali. 61: 633–637. doi:10.1128/JVI.61.2.633-637.1987. PMID  3543401.
  107. ^ Rosen, CA; Park R; Sodroski JG; Haseltine WA (1987). "Multiplesequence elements are required for regulation of human T-cell leukemia virus gene expression". Milliy fanlar akademiyasi materiallari. 84 (14): 4919–4923. Bibcode:1987PNAS...84.4919R. doi:10.1073/pnas.84.14.4919. PMC  305218. PMID  3037527.
  108. ^ Rosen, CA; Terwilliger E; Sodroski JG; Haseltine WA; Haseltine, W. A. (1988). "Intragenic cis-acting art Responsive Sequences of the Human Immunodeficiency Virus". Milliy fanlar akademiyasi materiallari. 85 (7): 2071–2075. Bibcode:1988PNAS...85.2071R. doi:10.1073/pnas.85.7.2071. PMC  279930. PMID  2832844.
  109. ^ Dayton, AI; Terwilliger EF; Potz J; Kowalski MM; Sodroski JG; Haseltine WA (1988). "Cis-Acting Sequences Responsive to the rev Gene Product of the Human Immunodeficiency Virus". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 1 (5): 441–452. PMID  2851651.
  110. ^ Rozen, C; Campbell K; Godin B; Sodroski J; Haseltine W; Rosen, C. A. (1988). "Subcellular Localization of Human Immunodeficiency Virus (HIV) Regulatory Proteins, tat and art". Virusologiya jurnali. 62 (7): 2498–2501. doi:10.1128/JVI.62.7.2498-2501.1988. PMC  253409. PMID  2836628.
  111. ^ Lu, Y; Touzjian N; Stenzel M; Dorfman T; Sodroski J; Haseltine WA (1990). "Identification of cis-acting repressive sequences within the Negative Regulatory Element of HIV-1". Virusologiya jurnali. 64 (10): 5226–5229. doi:10.1128/JVI.64.10.5226-5229.1990. PMC  248024. PMID  2398545.
  112. ^ Kalland, K; Langhoff E; Bos H; Gottlinger H; Haseltine W (1991). "Rex dependent nucleolar concentration of HTLV-1 env mRNA". The New Biologist. 3 (4): 389–397. PMID  2065024.
  113. ^ Cohen, EA; Terwilliger EF; Jalinoos Y; Proulx J; Sodroski JG; Haseltine WA (1990). "Identification of HIV-1 vpr Product Structure and Function". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 3 (1): 11–18. PMID  2136707.
  114. ^ Cohen, E; Dehni G; Sodroski J; Haseltine W (1990). "Human Immunodeficiency Virus vpr Product is a Virion-Associated Regulatory Protein". Virusologiya jurnali. 64 (6): 3097–3099. doi:10.1128/JVI.64.6.3097-3099.1990. PMC  249501. PMID  2139896.
  115. ^ Cohen, E; Lu Y; Gottlinger H; Dehni G; Sodroski J; Haseltine W (1990). "The T Open Reading Frame of Human Immunodeficiency Virus Type 1". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 3 (6): 601–608. PMID  2338618.
  116. ^ Koen; Terwilliger E; Haseltine WA (1991). Haseltine WA, Wong-Staal F (ed.). Genetic Structure and Regulation of HIV-1 (EA ed.). Raven Press. 451-456 betlar.
  117. ^ Cohen, EA; Terwilliger EF; Sodroski JG; Haseltine WA (1988). "OIV-1 ning vpu geni bilan kodlangan oqsilni aniqlash". Tabiat. 334 (6182): 532–534. Bibcode:1988Natur.334..532C. doi:10.1038 / 334532a0. PMID  3043230. S2CID  4372649.
  118. ^ Terwilliger, EF; Cohen EA; Lu Y; Sodroski JG; Haseltine WA (1989). "Functional Role of HIV-1 vpu". Milliy fanlar akademiyasi materiallari. 86 (13): 5163–5167. Bibcode:1989PNAS...86.5163T. doi:10.1073/pnas.86.13.5163. PMC  297578. PMID  2472639.
  119. ^ Yao, X-J; Gottlinger H, Haseltine WA and Cohen EA; Haseltine, W. A.; Cohen, E. A. (1992). "Envelope Glycoprotein and CD4 Independence of vpu-Facilitated Human Immunodeficiency Virus Type 1 Capsid Export". Virusologiya jurnali. 66 (8): 5119–5126. doi:10.1128/JVI.66.8.5119-5126.1992. PMC  241384. PMID  1629967.
  120. ^ Yao, X-J; Garzon S; Boisvert F; Haseltine WH; Cohen E (1993). "The effect of vpu on HIV-1 Induced Syncytia Formation". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 6 (2): 135–141. PMID  8094456.
  121. ^ Gabuzda, DH; Lawrence K; Langhoff E; Terwilliger EF; Dorfman T; Haseltine WA; Sodroski JG (1992). "The Role of vif in Replication of HIV-1 in CD4+ T Lymphocytes". Virusologiya jurnali. 66 (11): 6489–6494. doi:10.1128/JVI.66.11.6489-6495.1992. PMC  240141. PMID  1357189.
  122. ^ Terwilliger, EF; Langhoff E; Gabuzda D; Haseltine W; Haseltine, W. A. (1991). "Allelic variation in the effects of nef on HIV-1 replication". Milliy fanlar akademiyasi materiallari. 88 (23): 10971–10975. Bibcode:1991PNAS...8810971T. doi:10.1073/pnas.88.23.10971. PMC  53054. PMID  1720558.
  123. ^ Zazopoulos, E; Haseltine W (1992). "Mutational analysis of the HIV Eli nef function". Milliy fanlar akademiyasi materiallari. 88 (14): 6634–6638. doi:10.1073/pnas.89.14.6634. PMC  49556. PMID  1631166.
  124. ^ Zazopoulos, E; Haseltine, W (1993). "Disulfide bond formation in the human immunodeficiency virus type 1 Nef protein". Virusologiya jurnali. 67 (3): 1676–1680. doi:10.1128/JVI.67.3.1676-1680.1993. PMC  237542. PMID  8437238.
  125. ^ Zazopoulos, E; Haseltine WA (1992). "Effect of nef alleles on replication of human immunodeficiency virus type 1". Virusologiya jurnali. 194 (1): 20–27. doi:10.1006/viro.1993.1230. PMID  7683154.
  126. ^ Terwilliger, EF; Langhoff E, and Haseltine WA. (1991). Haseltine WA, Wong-Staal F (ed.). Genetic Structure and Regulation of HIV-1. Raven Press. pp. 457–471.
  127. ^ Haseltine, WA; Wong-Staal F (1988). "The Molecular Biology of the Human Immuno Deficiency Virus". Ilmiy Amerika. 256 (4): 52–62. doi:10.1038/scientificamerican1088-52. PMID  3072673.
  128. ^ Langhoff, E; Kalland KH; Haseltine WA (1993). "Early molecular replication of human immunodeficiency virus type 1 in cultured blood derived T helper dendritic cells". Klinik tadqiqotlar jurnali. 91 (6): 2721–2726. doi:10.1172/jci116512. PMC  443337. PMID  8514880.
  129. ^ Langhoff EL; Terwilliger E; Kalland KH; Poznansky M; Bos HJ; Bacon O; Sodroski J; And Haseltine WA (1991). Haseltine WA, Wong-Staal F (ed.). Genetic Structure and Regulation of HIV-1. Raven Press. pp. 511–525.
  130. ^ Fazely, F; Haseltine WA; Rodger RF; Ruprecht RM (1991). "Post-exposure Chemoprophylaxis with AZT or AZT Combined with Interferon-": Failure after inoculating Rhesus Monkeys with a High Dose of SIV". Qabul qilingan immunitet tanqisligi sindromlari jurnali. 4: 1093–1097.
  131. ^ Poznansky, M; Lever A; Bergeron L; Haseltine W; Sodroski J (1991). "Gene Transfer into Human Lymphocytes by a Defective Human Immunodeficiency Virus Type 1 Vector". Virusologiya jurnali. 65 (1): 532–536. doi:10.1128/JVI.65.1.532-536.1991. PMC  240552. PMID  1985215.
  132. ^ a b Alexander, Brian (2003). Rapture: How Biotech Became the New Religion. Asosiy kitoblar.
  133. ^ a b Winkelgren, Ingrid (202). The Gene Masters: How a new Breed of Scientific Entrepreneurs Raced for the Biggest Prize in Biology. Makmillan.
  134. ^ Cohen, J (October 2001). "Consulting Biotech's Oracle". Texnologiyalarni ko'rib chiqish: 70–75.
  135. ^ Herrera, Stephan (2005). "Profile: William Haseltine". Tabiat biotexnologiyasi. 23 (8): 913. doi:10.1038/nbt0805-913. PMID  16082351. S2CID  5839387.
  136. ^ Lowey, Karen (June 20, 2005). "William A Haseltine". Newsweek. 145 (24/25): 46.
  137. ^ Weeks, Linton (February 17, 1998). "Mr. Green Genes". Vashington Post.
  138. ^ "William Haseltine on Human Genome Science's Plan". BusinessWeek Onlayn. 2000 yil 12-iyun.
  139. ^ a b Shreeve, James (2004). The Genome War. Ballantin.
  140. ^ a b Haseltine, WA (March 1997). "Discovering Genes for New Medicines". Ilmiy Amerika. 276 (3): 92–97. doi:10.1038/scientificamerican0397-92. PMID  9046111.
  141. ^ Haseltine, WA (May 1998). "The Power of Genomics to transform the biotechnology industry". Tabiat biotexnologiyasi. 16: 25–27. doi:10.1038/5408. PMID  9591259. S2CID  26251256.
  142. ^ "Pandemic Perspectives: Interview with William Haseltine". Fan tarixi instituti. 2020 yil 28-may. Olingan 1 iyun 2020.
  143. ^ "NSF: Abt Report on "The Emergence of Tissue Engineering as a Research Field"". www.nsf.gov.
  144. ^ Bailey, Ron (2005). Liberation Biology: The Scientific and Moral Case for the Biotech Revolution. Prometey kitoblari.
  145. ^ Alexander, Brian. "Don't Die, Stay Pretty: The exploding science of superlongevity". Simli.
  146. ^ Fahey, Gregory M (July 2002). "Dr. William Haseltine on Regenerative Medicine, Aging and Human Immortality". Hayotni uzaytirish. 8 (7): 58.
  147. ^ Haseltine, WA (6 July 2004). "The Emergence of Regenerative Medicine: A New Field and a New Society". E-biomed: The Journal of Regenerative Medicine. 2 (4): 17–23. doi:10.1089/152489001753309652.
  148. ^ Yeung, Jessie, Adam Renton and Angela Dewan (14 October 2020). ""Herd immunity is another word for mass murder," expert says". CNN. Olingan 14 oktyabr 2020.
  149. ^ Priya Anant; Singh PV; Bergkvist S; George A; Haseltine W (2012). Improving the Health of Mother and Child: Solutions from India. Access Health International.
  150. ^ Widén, Sofia; Haseltine, William A. (2017-07-01). Aging with Dignity: Innovation and Challenge in Sweden – The Voice of Elder Care Professionals. Nordic Academic Press. ISBN  9789188168900.

Tashqi havolalar